Skip to main content
Search
Search
Advanced Search
Skip main navigation
Free access
Short Communication
6 May 2021

DAPA-RWE: a retrospective multicenter study comparing dapagliflozin and sitagliptin in patients with Type 2 diabetes treated under routine clinical practice in Spain

Authors: Cristobal Morales https://orcid.org/0000-0003-0348-826X [email protected], Virginia Bellido, Cristina Tejera, Fernando Goñi, Rafael Palomares, Cristina Sevillano, Diego Bellido, Alfonso Soto, Miguel Ángel Mangas, Manuel A Botana, and Irene CaballeroAuthor Info & Affiliations
Volume 10, Number 10
https://doi.org/10.2217/cer-2020-0264
PDFFormats

Abstract

Background: Weight reduction and glycemic control are key goals during Type 2 diabetes management. However, there are few country-specific, real-world data on cotransporter 2 inhibitors. Materials & methods: DAPA-RWE was a retrospective, multicenter study comparing the efficacy of dapagliflozin versus sitagliptin in Type 2 diabetes patients in Spain. Results: The study population comprised 1046 patients (594 with dapagliflozin, 452 with sitagliptin). Age was 61.8 ± 10.0 and 66.2 ± 11.4 years and glycosylated hemoglobin (HbA1c) 8.9 and 8.8%, respectively. The main end point (reduction in weight and HbA1c) was reached by 24.4 and 56.1% of patients, respectively; p < 0.05. This was confirmed with a propensity score matching analysis balanced for obesity-related variables at baseline. Conclusion: DAPA-RWE confirmed dapagliflozin to be more effective than sitagliptin in reducing HbA1c and weight.

Supplementary Material

File (suppl_file.zip)
File (supplementary table 1.docx)
File (supplementary table 2.docx)

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321(7258), 405–512 (2000).
PubMed
Google Scholar
• Study shows that reducing glycosylated hemoglobin (HbA1c) levels is associated with a decrease in the risk of complications.
2.
Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in Type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6), 1364–4379 (2012).
PubMed
Google Scholar
3.
Khunti K, Davies M. Glycaemic goals in patients with Type 2 diabetes: current status, challenges and recent advances. Diabetes Obes. Metab. 12(6), 474–484 (2010).
PubMed
Google Scholar
4.
Pollack MF, Purayidathil FW, Bolge SC, Williams SA. Patient-reported tolerability issues with oral antidiabetic agents: associations with adherence; treatment satisfaction and health-related quality of life. Diabetes Res. Clin. Pract. 87(2), 204–410 (2010).
PubMed
Google Scholar
• Suggests that improving tolerability of antidiabetic drugs may increase patient satisfaction, medication adherence and quality of life.
5.
Soriguer F, Goday A, Bosch-Comas A et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the [email protected] Study. Diabetologia 55(1), 88–83 (2012).
PubMed
Google Scholar
•• In Spain, the prevalence of diabetes reaches 14%.
6.
de Pablos-Velasco P, Parhofer KG, Bradley C et al. Current level of glycaemic control and its associated factors in patients with Type 2 diabetes across Europe: data from the PANORAMA study. Clin. Endocrinol. (Oxf). 80(1), 47–76 (2014).
PubMed
Google Scholar
7.
Elliott L, Fidler C, Ditchfield A, Stissing T. Hypoglycemia event rates: a comparison between real-world data and randomized controlled trial populations in insulin-treated diabetes. Diabetes Ther. 7(1), 45–50 (2016).
PubMed
Google Scholar
• Suggests that randomized clinical trials are likely to underestimate the burden of hypoglycemia in clinical practice.
8.
Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of Type 2 diabetes. Diabetes Metab. Syndr. Obes. 5, 313–327 (2012).
PubMed
Google Scholar
9.
Fadini GP, Zatti G, Baldi I et al. Use and effectiveness of dapagliflozin in routine clinical practice: an Italian multicentre retrospective study. Diabetes Obes. Metab. 20(7), 1781–1786 (2018).
PubMed
Google Scholar
• In this real-world study, dapagliflozin reduced HbA1c by 0.7%, bodyweight by 2.7 kg and systolic blood pressure by 3.0 mm Hg.
10.
Wilding J, Godec T, Khunti K et al. Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with Type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. BMC Med. 16(1), 116 (2018).
PubMed
Google Scholar
|